Karuna therapeutics, inc. (KRTX)

CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19
Cash flows from operating activities
Net loss

-40,610

-43,957

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

11,098

12,568

0

0

0

Non-cash interest income

1,705

1,260

0

0

0

Non-cash interest income, net (Note 4)

-

11

0

0

0

Accretion of debt discount (Note 4)

-

945

0

0

0

Change in fair value of derivative liability (Note 4)

-

-135

0

0

0

Depreciation and amortization expense

69

58

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

2,946

1,600

0

0

0

Right-of-use assets

0

-

-

-

-

Accounts payable

-283

278

0

0

0

Accrued expenses

690

1,815

0

0

0

Deferred lease obligation

-

106

0

0

0

Operating lease liability

0

-

-

-

-

Net cash used in operating activities

-33,150

-30,923

0

0

0

Cash flows from investing activities
Purchases of short-term investments

0

-

-

-

-

Maturities of short-term investments

105,000

50,000

0

0

0

Acquisition of property and equipment

174

115

0

0

0

Net cash (used in) provided by investing activities

-189,744

-174,335

0

0

0

Cash flows from financing activities
Proceeds from issuance of convertible notes

-

3,128

0

0

0

Proceeds from exercise of stock options

0

-

-

-

-

Proceeds from exercise of warrant

-

58

0

0

0

Payment of deferred offering costs

-

2,409

0

0

0

Net cash provided by financing activities

329,298

405,283

0

0

0

Net increase in cash, cash equivalents and restricted cash

106,404

200,025

0

0

0

Supplemental disclosures of cash flows information
Lease liabilities arising from obtaining right-of-use assets

0

-

-

-

-

Purchases of property and equipment included in accounts payable and accrued expenses

0

-

-

-

-

Deferred offering costs included in accrued expenses

0

-

-

0

0

Conversion of convertible notes, accrued interest and discount upon conversion to preferred stock

-

7,102

0

0

0

Series B Redeemable Convertible Preferred Stock
Proceeds from issuance of Series B redeemable convertible preferred stock, net of issuance costs

-

74,825

0

0

0